Question · asked by 1 review

IM erythropoietin + IV iron sucrose vs IV iron sucrose + IM placebo: Number of responders ‐ disease activity not stated (12 weeks)

IM erythropoietin + IV iron sucrose showed no clear difference in number of responders ‐ disease activity not stated (12 weeks) compared with IV iron sucrose + IM placebo (low certainty).

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
IM erythropoietin + IV iron sucrose vs IV iron sucrose + IM placebo
Number of responders ‐ disease activity not stated (12 weeks) · IBD patients
IM erythropoietin + IV iron sucrose showed no clear difference in number of responders ‐ disease activity not stated (12 weeks) compared with IV iron sucrose + IM placebo (low certainty).
Interventions for treating iron deficiency anaemia in inflammatory bowel disease (2021) · Cochrane Headline outcomes only
RR 1.2 [0.9, 1.61]1 study · 40 participantsLow

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Interventions for treating iron deficiency anaemia in inflammatory bowel disease
2021 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.